Cargando…

Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2

BACKGROUND & AIMS: The albumin–bilirubin (ALBI) grade/score is derived from a validated nomogram to objectively assess prognosis and liver function in patients with hepatocellular carcinoma (HCC). In this post hoc analysis, we assessed prognosis in terms of survival by baseline ALBI grade and mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kudo, Masatoshi, Galle, Peter R., Brandi, Giovanni, Kang, Yoon-Koo, Yen, Chia-Jui, Finn, Richard S., Llovet, Josep M., Assenat, Eric, Merle, Philippe, Chan, Stephen L., Palmer, Daniel H., Ikeda, Masafumi, Yamashita, Tatsuya, Vogel, Arndt, Huang, Yi-Hsiang, Abada, Paolo B., Yoshikawa, Reigetsu, Shinozaki, Kenta, Wang, Chunxiao, Widau, Ryan C., Zhu, Andrew X.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772786/ https://www.ncbi.nlm.nih.gov/pubmed/33392490 http://dx.doi.org/10.1016/j.jhepr.2020.100215

Ejemplares similares

Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
por: Llovet, Josep M., et al.
Publicado: (2022)

Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
por: Zhu, Andrew X., et al.
Publicado: (2021)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis
por: Park, Joon Oh, et al.
Publicado: (2016)

Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
por: Finn, Richard S, et al.
Publicado: (2022)

Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
por: Chau, Ian, et al.
Publicado: (2018)

Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study
por: Shao, Guoliang, et al.
Publicado: (2022)

Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials
por: Zhu, Andrew X, et al.
Publicado: (2020)

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
por: Yoshikawa, Takaki, et al.
Publicado: (2019)

The ALBI score: From liver function in patients with HCC to a general measure of liver function
por: Toyoda, Hidenori, et al.
Publicado: (2022)

In albis : poemas, 1979-1990 /
por: Magaña, Gabriel, 1944-

Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy
por: Choucair, Khalil, et al.
Publicado: (2021)

ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240
por: Vogel, Arndt, et al.
Publicado: (2021)

Gran Sasso: Reaching the parts that accelerators cannot reach
Publicado: (1995)

Reaching for the stars
Publicado: (1971)

Reaching for empire
por: Weisberger, Bernard A.
Publicado: (1964)

REACH – an overview
por: Čihák, Rostislav
Publicado: (2009)

Reaching the teachers
Publicado: (2001)

Reach further
por: Christiansen, Jens Sandahl
Publicado: (2012)

Reaching Heaven
Publicado: (1906)

Reaching the limit
por: Bolognesi, Benedetta, et al.
Publicado: (2018)

Reaching the unreached
por: KAWAKAMI, Tsuyoshi
Publicado: (2018)

Growth and Reach
por: Golladay, Gregory J.
Publicado: (2020)

Reaching out
por: Mack, Katherine, et al.
Publicado: (2020)

Reaching Beyond
por: Alexander, Philip
Publicado: (2023)

The world within reach: An image database of reach-relevant environments
por: Josephs, Emilie L., et al.
Publicado: (2021)

Dataset of reaching behavior for reward in social situations in mice
por: Ukezono, Masatoshi, et al.
Publicado: (2021)

Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy
por: Su, Ting-Shi, et al.
Publicado: (2019)

Combination Of ALBI And APRI To Predict Post-Hepatectomy Liver Failure After Liver Resection For HBV-Related HCC Patients
por: Mai, Rong-yun, et al.
Publicado: (2019)

Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection
por: Tsai, Yu-Chieh, et al.
Publicado: (2021)

Comparative evaluation of ALBI, MELD, and Child-Pugh scores in prognosis of cirrhosis: is ALBI the new alternative?
por: Fragaki, Maria, et al.
Publicado: (2019)

Collimation and β * reach
por: Bruce, R, et al.
Publicado: (2014)

${\beta*}$-reach in 2017
por: Bruce, R, et al.
Publicado: (2017)

Protons reach the SPS
Publicado: (1976)

Collider reaches for the top
Publicado: (1984)

Spines reach out
por: LeBrasseur, Nicole
Publicado: (2005)

Extending Our Reach
por: Wilcox, Lynne S.
Publicado: (2004)

Wellness Within REACH
Publicado: (2006)

REACHing for chemical safety.
por: Brown, Valerie J
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_t0hlc7n0983u61f3fohvai4vap